# Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

> **NCT01434316** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 121 (actual)

## Conditions studied

- Advanced Malignant Solid Neoplasm

## Interventions

- **DRUG:** Dinaciclib
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01434316
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-11-11
- **Primary completion:** 2023-03-28
- **Final completion:** 2026-08-02
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01434316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01434316, "Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01434316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*